Nuveen Asset Management LLC Sells 171,939 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Nuveen Asset Management LLC lessened its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,013,533 shares of the company's stock after selling 171,939 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.41% of Roivant Sciences worth $35,650,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC raised its position in Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after acquiring an additional 156,527 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after purchasing an additional 2,404,232 shares during the last quarter. Two Seas Capital LP raised its holdings in shares of Roivant Sciences by 4.6% in the 4th quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock valued at $120,285,000 after purchasing an additional 442,914 shares during the period. Invesco Ltd. raised its holdings in shares of Roivant Sciences by 49.7% in the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after purchasing an additional 3,159,603 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Roivant Sciences by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company's stock valued at $91,968,000 after purchasing an additional 26,727 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Activity at Roivant Sciences

In related news, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the transaction, the insider now directly owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 315,522 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the completion of the sale, the chief operating officer now directly owns 959,457 shares of the company's stock, valued at $10,611,594.42. This represents a 24.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,223,959 shares of company stock worth $13,450,035 in the last ninety days. 7.90% of the stock is owned by company insiders.

Roivant Sciences Trading Down 0.6%

Shares of NASDAQ:ROIV traded down $0.07 during trading on Monday, reaching $10.87. 2,442,270 shares of the stock were exchanged, compared to its average volume of 5,579,306. The firm has a market cap of $7.76 billion, a PE ratio of -72.46 and a beta of 1.23. The stock has a 50-day moving average price of $10.53 and a 200-day moving average price of $11.05. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Monday, April 21st.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.